{"name": "Cequent Pharmaceuticals",
 "permalink": "cequent-pharmaceuticals",
 "crunchbase_url": "http://www.crunchbase.com/company/cequent-pharmaceuticals",
 "homepage_url": "http://www.cequentpharma.com/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": 2006,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "info@cequentpharma.com",
 "phone_number": "617.995.7940",
 "description": "Early Stage Biopharmaceutical",
 "created_at": "Fri Nov 13 01:23:52 UTC 2009",
 "updated_at": "Sun Feb 13 20:05:40 UTC 2011",
 "overview": "\u003Cp\u003EAn early-stage biopharmaceutical company, Cequent is pioneering the development of novel therapeutics to prevent and treat a wide range of human diseases \u00e2\u20ac\u201c from inflammatory diseases to cancer \u00e2\u20ac\u201c based on the company\u00e2\u20ac\u2122s proprietary technology, TransKingdom RNA interference (tkRNAi). Cequent\u00e2\u20ac\u2122s first products, now in pre-clinical development, are drug candidates targeting colon-cancer prevention and inflammatory bowel disease. The company designed its powerful tkRNAi technology to deactivate specific disease-causing genes safely and effectively, using non-pathogenic bacteria as an engine to produce and deliver RNAi directly into cells. It is based on ground-breaking scientific research originating at the Institut Pasteur (Paris, France) and at the Beth Israel Deaconess Medical Center/Harvard Medical School. A privately held company based in Cambridge, Massachusetts, Cequent was established in 2006.  In July 2010, Cequent Pharmaceuticals was acquired by Marina Biotech, Inc (formerly MDRNA, Inc) for $46M.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       41],
      "assets/images/resized/0006/6015/66015v1-max-150x150.png"],
     [[250,
       69],
      "assets/images/resized/0006/6015/66015v1-max-250x250.png"],
     [[299,
       83],
      "assets/images/resized/0006/6015/66015v1-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": true,
    "title": "President, CEO",
    "person":
     {"first_name": "Peter",
      "last_name": "Parker",
      "permalink": "peter-parker",
      "image": null}},
   {"is_past": true,
    "title": "CFO",
    "person":
     {"first_name": "Lisa",
      "last_name": "Velardo",
      "permalink": "lisa-velardo",
      "image": null}},
   {"is_past": true,
    "title": "VP Operations",
    "person":
     {"first_name": "Susie",
      "last_name": "Truong Harborth",
      "permalink": "susie-truong",
      "image": null}},
   {"is_past": true,
    "title": "Chief Business Officer",
    "person":
     {"first_name": "Ted",
      "last_name": "Hibben",
      "permalink": "ted-hibben",
      "image": null}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$12.4M",
 "funding_rounds":
  [{"round_code": "a",
    "source_url": "http://www.cequentpharma.com/NovartisRelease.pdf",
    "source_description": "Cequent Pharmaceuticals",
    "raised_amount": 9000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2007,
    "funded_month": 6,
    "funded_day": 18,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Novartis Option Fund",
         "permalink": "novartis-option-fund",
         "image":
          {"available_sizes":
            [[[150,
               19],
              "assets/images/resized/0007/3160/73160v1-max-150x150.png"],
             [[250,
               32],
              "assets/images/resized/0007/3160/73160v1-max-250x250.png"],
             [[373,
               49],
              "assets/images/resized/0007/3160/73160v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Ampersand Capital Partners",
         "permalink": "ampersand-ventures",
         "image":
          {"available_sizes":
            [[[150,
               43],
              "assets/images/resized/0002/2837/22837v1-max-150x150.jpg"],
             [[208,
               60],
              "assets/images/resized/0002/2837/22837v1-max-250x250.jpg"],
             [[208,
               60],
              "assets/images/resized/0002/2837/22837v1-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Nexus Medical Partners",
         "permalink": "nexus-medical-partners",
         "image":
          {"available_sizes":
            [[[150,
               70],
              "assets/images/resized/0005/4129/54129v1-max-150x150.jpg"],
             [[167,
               79],
              "assets/images/resized/0005/4129/54129v1-max-250x250.jpg"],
             [[167,
               79],
              "assets/images/resized/0005/4129/54129v1-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Pappas Ventures",
         "permalink": "pappas-ventures",
         "image":
          {"available_sizes":
            [[[150,
               131],
              "assets/images/resized/0004/9245/49245v1-max-150x150.png"],
             [[164,
               144],
              "assets/images/resized/0004/9245/49245v1-max-250x250.png"],
             [[164,
               144],
              "assets/images/resized/0004/9245/49245v1-max-450x450.png"]],
           "attribution": null}},
       "person": null}]},
   {"round_code": "b",
    "source_url": "http://www.xconomy.com/boston/2009/11/12/massachusetts-startup-funding-slowed-way-down-in-october-but-early-stage-deals-gained/",
    "source_description": "Xconomy Boston",
    "raised_amount": 3400000.0,
    "raised_currency_code": "USD",
    "funded_year": 2009,
    "funded_month": 10,
    "funded_day": null,
    "investments":
     []}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "One Kendall Square",
    "address2": "Building 700, First Floor",
    "zip_code": "02139",
    "city": "Cambridge",
    "state_code": "MA",
    "country_code": "USA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [],
 "external_links":
  []}